Pyk2 promotes tumor progression in multiple myeloma
Open Access
- 23 October 2014
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 124 (17) , 2675-2686
Abstract
Key Points: Pyk2 plays a tumor-promoting role in MM progression via modulation of the Wnt/β-catenin signaling pathway. Pyk2 inhibitors represent a new therapeutic option against MM.Keywords
This publication has 47 references indexed in Scilit:
- Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple MyelomaPLOS ONE, 2013
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor MicroenvironmentMolecular Cancer Therapeutics, 2011
- Compensatory Function of Pyk2 Protein in the Promotion of Focal Adhesion Kinase (FAK)-null Mammary Cancer Stem Cell Tumorigenicity and Metastatic ActivityJournal of Biological Chemistry, 2011
- Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myelomaLeukemia, 2011
- Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAKJournal of Cell Biology, 2008
- Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosisProceedings of the National Academy of Sciences, 2007
- Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myelomaProceedings of the National Academy of Sciences, 2007
- Focal adhesion kinase: in command and control of cell motilityNature Reviews Molecular Cell Biology, 2005
- Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient miceNature, 1995